O IMPACTO DA REGULAÇÃO DO SISTEMA ENDOCANABINOIDE NA FARMACOTERAPIA DA ANSIEDADE E DO ESTRESSE

This article addresses the impact of regulation of the endocannabinoid system on the pharmacotherapy of anxiety and stress, topics of increasing relevance in neuroscience and pharmacology. The endocannabinoid system, composed of receptors, endocannabinoids and enzymes responsible for their synthesis and degradation, plays a fundamental role in modulating several physiological functions, including the regulation of stress and anxiety. Cannabidiol (CBD), a phytocannabinoid, has stood out for its anxiolytic and modulating effects on the endocannabinoid system, presenting itself as a promising therapeutic alternative for anxiety disorders. The objective of the study was to analyze the therapeutic effects of regulating the endocannabinoid system in the treatment of anxiety and stress, focusing on the benefits and limitations of using CBD. To this end, a bibliographic review of studies published between 2010 and 2024 was carried out, using databases such as PubMed, SciELO and Google Scholar. Inclusion criteria involved peer-reviewed studies that addressed the relationship between the endocannabinoid system and anxiety disorders. The results showed that CBD can significantly reduce symptoms of anxiety and stress, with few side effects. However, there are still gaps regarding optimal dosage and drug interactions, which limits its widespread clinical adoption. Regulation of the medicinal use of cannabis has also proven to be an obstacle in several countries. It is concluded that, despite the challenges, the use of cannabinoids such as CBD represents a promising approach, requiring greater investment in clinical research and adequate regulation.